http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Seelos Therapeutics (SEEL) Issues Letter to its Stockholders
-
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
-
Seelos Therapeutics (SEEL) Announces Selection of SLS-002 for Inclusion in U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for PTSD
-
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post
-
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
-
Seelos Therapeutics (SEEL) Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
-
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
-
Seelos Therapeutics (SEEL) Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
-
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
-
Seelos Therapeutics (SEEL) Reports Top Line Results from SLS-002 Phase II Study in Adults
-
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
-
Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
-
Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major D
-
Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
-
Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
-
Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
-
Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program
-
Seelos Therapeutics Announces Business Update on its Key Programs
-
Seelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference
-
Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
-
Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
-
Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
-
Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event
-
Seelos Therapeutics (SEEL) Reports Strong SLS-004 Data
-
Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
-
Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022
-
Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022
-
Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day
-
Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event
-
Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia
-
Seelos Therapeutics (SEEL) to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program
-
Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the A
-
Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients wi
-
Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference
-
Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences
-
Seelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004
-
Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform
-
Seelos Therapeutics (SEEL) Reports Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004
-
Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 i
-
Seelos Therapeutics (SEEL) Receives Notice of Allowance in the U.S. for an Additional Patent for SLS-007
-
Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
-
Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
-
Seelos Therapeutics to Participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference
-
Seelos Therapeutics (SEEL) Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002
-
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Com
-
Seelos Therapeutics Receives an Acknowledgement Letter of a Clinical Trial Notification from the Australian Government Department of Health Therapeutic Goods Administration for a Pilot Study of SLS-00
-
Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update
-
Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
-
Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event